AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06541808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical Vagus Nerve Stimulation (Intermediate Intensity)
Description: The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 3 sessions of 2 minutes, with 2 minutes of rest for each side. stimulation will be provided only once for the experiment duration.
Study NCT06541808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical Vagus Nerve Stimulation (High Intensity)
Description: The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 8 consecutive minutes for each side, only once for the experiment duration.
Study NCT06541808 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mechanical Vagus Nerve Stimulation
Description: Participants will be treated with a fake vagus stimulation by letting the operator hold the neck of the participant in one hand and placing the other hand on the abdomen without any stretch on the vagus nerve
Study NCT06252714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defecation Posture Modification Device
Description: Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
Study NCT05525741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non segmental vitiligo
Description: The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Study NCT05525741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Volunteers
Description: The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Study NCT06259357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized protective mechanical ventilation in prone position
Description: Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
Study NCT06556485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Preventive ablation therapy
Study NCT06556485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Optimal medical therapy
Study NCT05015504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
Study NCT06278051 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban granules for oral suspension
Description: Treatment dose and period decided by its prescription
Study NCT06278051 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Treatment dose and period decided by its prescription
Study NCT05071729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant on Day 1.
Study NCT05570045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colos Gain
Description: Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks.
Study NCT06410079 — intervention group
Intervention type: PROCEDURE
Intervention: total hip replacement
Description: Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
Study NCT06149819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain
Description: trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
Study NCT04785391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection for NEPHROCLEAR CCL14 Test
Description: Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
Study NCT04810520 — intervention group
Intervention type: OTHER
Intervention: Point-of-care ultrasound with tele-supervision
Description: Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
Study NCT04810520 — intervention group
Intervention type: OTHER
Intervention: Point-of-care ultrasound without tele-supervision
Description: Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
Study NCT04647669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: 200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
Study NCT04647669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: 100 mg capsules twice daily every 12 h for 10 days taken with or without food.
Study NCT04647669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
Study NCT04647669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Treatment according to local hospital protocol
Study NCT05383911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCD Shared Decision-Making Toolkit for AYAs - including VR
Description: The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including virtual reality, online (videos, animations, articles), and print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
Study NCT05383911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCD Shared Decision-Making Toolkit for AYAs - without VR
Description: The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including online videos, animations, and articles as well as print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
Study NCT06473051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Original set
Description: The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.
Study NCT06473051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted set
Description: The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
Study NCT05772520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
Study NCT06046248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: 200mg PO QD x 24 cycles (28-day cycle)
Study NCT06046248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
Study NCT05444881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention (Headspace TM)
Description: A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages).
Study NCT05225103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFETY-Acute intervention
Description: The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
Study NCT06163326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 50 mg capsule once daily
Study NCT06163326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 100 mg
Description: Ritlecitinib 100 mg capsule once daily
Study NCT06163326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsule once daily
Study NCT05504707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 - primed Dendritic cells
Description: Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million
Study NCT05504707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER3 - primed Dendritic cells
Description: Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million
Study NCT06073704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy (aPDT)
Description: Scaling and root planing followed by antimicrobial photodynamic therapy
Study NCT06073704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment of scaling and root planing
Study NCT04979598 — intervention group
Intervention type: OTHER
Intervention: Home exercise program
Description: A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
Study NCT06141083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI188 Probiotic
Description: take two tablets per day
Study NCT06141083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take two tablets per day
Study NCT00828685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRPP
Description: Closed reduction, percutaneous pinning
Study NCT00828685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF
Description: Open reduction, internal fixation
Study NCT05553626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left bundle branch pacing
Description: Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
Study NCT05553626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
Study NCT05553626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT/CRTD device
Study NCT05553626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT/CRTD device
Study NCT05789771 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
Study NCT05789771 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
Study NCT05789771 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib 200 mg orally every 12 hours
Study NCT04564326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve Group block
Description: Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
Study NCT05143151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD276 CAR-T cells
Description: CD276 CAR-T cells infusion
Study NCT04867902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology-Motivational Interviewing Intervention
Description: Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
Study NCT04564326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facia Iliaca block
Description: Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
Study NCT04564326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
Study NCT06419647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Daily mood tracking tasks
Study NCT05907473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: Patients in this group will play balance-based games with the Virtual Reality System.
Study NCT05907473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
Study NCT05301023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized antibiotic therapy
Description: Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
Study NCT05301023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic therapy
Description: Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
Study NCT05943067 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD45RA depleted donor lymphocyte infusion (DLI)
Description: CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
Study NCT05282472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CPET without mask
Description: Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
Study NCT05282472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CPET with mask
Description: A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
Study NCT06047743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating unilateral Isometric Handgrip Exercise
Description: Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
Study NCT06047743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dominant knee extension Isometric Exercise
Description: Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
Study NCT06394401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BAL:GLU
Description: 80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet